Skip to main content

iRhythm Holdings, Inc. (IRTC) Stock Analysis

Falling Knife setup

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Medical Devices

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $114.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).

iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear) and proprietary cloud-based ZEUS analysis software via Medicare-enrolled IDTFs. It is the market leader delivering over 70% of LTCM services in the U.S.; ~24% of... Read more

$114.00+40.5% A.UpsideScore 5.6/10#15 of 40 Medical Devices
QualityF-score6 / 9FCF yield1.52%
Stop $109.12Target $160.20(analyst − 13%)A.R:R 3.4:1
Analyst target$184.14+61.5%14 analysts
$160.20our TP
$114.00price
$184.14mean
$255

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $114.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Score 5.6/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Recent Developments — iRhythm Holdings, Inc.

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Strong growth profile
Risks
Concentration risk — Product: iRhythm Services
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0)
Leverage penalty (D/E 4.5): -1.5

Key Metrics

P/E (TTM)
P/E (Fwd)109.3
Mkt Cap$3.7B
EV/EBITDA-351.6
Profit Mgn-3.5%
ROE-22.4%
Rev Growth25.7%
Beta1.33
DividendNone
Rating analysts21

Quality Signals

Piotroski F6/9MoatNarrow

Concentration Risks(10-K Item 1A)

  • HIGHProductiRhythm Services
    10-K Item 1A: 'Our current revenue is dependent on orders for our iRhythm Services, and we expect that reimbursement for our iRhythm Services will account for substantially all our revenue for the foreseeable future.'
  • LOWregulatoryMedicare program (CMS)24%
    10-K Item 1A: 'During the year ended December 31, 2025, we received approximately 24% of our total revenue from the Medicare program through CMS.'

Material Events(8-K, last 90d)

  • 2026-04-01Item 4.01HIGH
    PricewaterhouseCoopers LLP dismissed as independent registered public accounting firm on March 30, 2026. No disagreements or reportable events in PwC audit reports for FY2025 and FY2024. Successor auditor not named in this filing.
    SEC filing →
  • 2026-03-12Item 5.02LOW
    Jason Patten appointed as director and Audit Committee member effective March 12, 2026, for term expiring at 2026 Annual Meeting. Board determined Patten is independent under Nasdaq standards.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Rsi
3.5
Volume
4.8
Volume distribution (falling OBV)Below 200-MA, MA slope -1.9%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
2.0
Quality Rank
2.3
Growth Rank
8.5
Industry growth leader
GatesMomentum 2.1<4.5Death cross (50MA < 200MA)A.R:R 3.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 75d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
37 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $112.50Resistance $129.97

Price Targets

$109
$160
A.Upside+40.5%
A.R:R3.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-30 (75d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IRTC stock a buy right now?

Sell if holding. Momentum 2.1/10 is below the 5.0 floor at $114.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Prior stop was $109.12. Score 5.6/10, moderate confidence.

What is the IRTC stock price target?

Take-profit target: $160.20 (+40.5% upside). Prior stop was $109.12. Stop-loss: $109.12.

What are the risks of investing in IRTC?

Concentration risk — Product: iRhythm Services; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Leverage penalty (D/E 4.5): -1.5.

Is IRTC overvalued or undervalued?

iRhythm Holdings, Inc. trades at a P/E of N/A (forward 109.3). TrendMatrix value score: 6.8/10. Verdict: Sell.

What do analysts say about IRTC?

21 analysts cover IRTC with a consensus score of 4.3/5. Average price target: $184.

What does iRhythm Holdings, Inc. do?iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear)...

iRhythm provides ambulatory cardiac monitoring services using its Zio patch biosensors (up to 14-day continuous wear) and proprietary cloud-based ZEUS analysis software via Medicare-enrolled IDTFs. It is the market leader delivering over 70% of LTCM services in the U.S.; ~24% of 2025 revenue came from Medicare.

Related stocks: GMED (Globus Medical, Inc.) · DXCM (DexCom, Inc.) · PODD (Insulet Corporation) · ZBH (Zimmer Biomet Holdings, Inc.) · ENOV (Enovis Corporation)